AGA Luminal and Fistulizing Crohn’s Disease Pocket Guide (Janssen)

Luminal and Fistulizing Crohn’s Disease Pocket Guide

AGA Luminal and Fistulizing Crohn’s Disease GUIDELINES brought to you courtesy of Guideline Central.

Issue link: https://eguideline.guidelinecentral.com/i/1399717

Contents of this Issue

Navigation

Page 9 of 13

Treatment 10 Figure 2. Medical Management of Adult Outpatients With Moderate to Severe Fistulizing Crohn's Disease • Recommend the use of biologic agents in combination with an antibiotic over a biologic drug alone for the induction of fistula remission (strong, moderate) Biologic therapy • Recommend infliximab over no treatment for induction and maintenance of fistula remission (strong, moderate) • Suggest adalimumab, ustekinumab, or vedolizumab over no treatment for induction and maintenance of fistula remission (conditional, low) Comment: Evidence suggest certolizumab pegol may not be effective for induction of fistula remission. Adult outpatients with active perianal disease without perianal abscess • Suggest AGAINST the use of antibiotics alone over no treatment for the induction of fistula remission (conditional, low) Antibiotics

Articles in this issue

view archives of AGA Luminal and Fistulizing Crohn’s Disease Pocket Guide (Janssen) - Luminal and Fistulizing Crohn’s Disease Pocket Guide